Innovation Pharmaceuticals Inc (IPIX)

[EYCBGO]

https://www.eurekalert.org/pub_releases/2020-06/gmu-nsa060520.php

That was only part of the study

Aarthi Narayanan, Associate Professor, National Center for Biodefense and Infectious Diseases, received $35,000 from Innovation Pharmaceuticals, Inc., for a project in which she is examining the use of Brilacidin for the treatment of coronavirus infections.

Brilacidin is an investigational new drug. It is a polymer-based antibiotic currently in human clinical trials. It represents a new class of antibiotics called host defense protein mimetics, or HDP-mimetics, which are non-peptide synthetic small molecules modeled after host defense peptides.

As part of this project, Narayanan will first determine the EC50 values, or the concentration of the drug that gives a half-maximal response.